Orally administered Lactobacillus rhamnosus modulates the respiratory immune response triggered by the viral pathogen-associated molecular pattern poly(I:C) by Villena, Julio Cesar et al.
Villena et al. BMC Immunology 2012, 13:53
http://www.biomedcentral.com/1471-2172/13/53RESEARCH ARTICLE Open AccessOrally administered Lactobacillus rhamnosus
modulates the respiratory immune response
triggered by the viral pathogen-associated
molecular pattern poly(I:C)
Julio Villena1,2*, Eriko Chiba2, Yohsuke Tomosada2, Susana Salva1, Gabriela Marranzino1, Haruki Kitazawa2
and Susana Alvarez1*Abstract
Background: Some studies have shown that probiotics, including Lactobacillus rhamnosus CRL1505, had the
potential to beneficially modulate the outcome of certain bacterial and viral respiratory infections. However, these
studies did not determine the mechanism(s) by which probiotics contribute to host defense against respiratory
viruses.
Results: In this work we demonstrated that orally administered Lactobacillus rhamnosus CRL1505 (Lr1505) was able
to increase the levels of IFN-γ, IL-10 and IL-6 in the respiratory tract and the number of lung CD3+CD4+IFN-γ+
T cells. To mimic the pro-inflammatory and physiopathological consecuences of RNA viral infections in the lung, we
used an experimental model of lung inflammation based on the administration of the artificial viral pathogen-
associated molecular pattern poly(I:C). Nasal administration of poly(I:C) to mice induced a marked impairment of
lung function that was accompanied by the production of pro-inflammatory mediators and inflammatory cell
recruitment into the airways. The preventive administration of Lr1505 reduced lung injuries and the production of
TNF-α, IL-6, IL-8 and MCP-1 in the respiratory tract after the challenge with poly(I:C). Moreover, Lr1505 induced a
significant increase in lung and serum IL-10. We also observed that Lr1505 was able to increase respiratory IFN-γ
levels and the number of lung CD3+CD4+IFN-γ+ T cells after poly(I:C) challenge. Moreover, higher numbers of both
CD103+ and CD11bhigh dendritic cells and increased expression of MHC-II, IL-12 and IFN-γ in these cell populations
were found in lungs of Lr1505-treated mice. Therefore, Lr1505 treatment would beneficially regulate the balance
between pro-inflammatory mediators and IL-10, allowing an effective inflammatory response against infection and
avoiding tissue damage.
Conclusions: Results showed that Lr1505 would induce a mobilization of cells from intestine and changes in
cytokine profile that would be able to beneficially modulate the respiratory mucosal immunity. Although deeper
studies are needed using challenges with respiratory viruses, the results in this study suggest that Lr1505, a potent
inducer of antiviral cytokines, may be useful as a prophylactic agent to control respiratory virus infection.
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Studies in animal models have identified strong immu-
nomodulatory effects of some non-pathogenic bacteria
and provided evidence that some orally administered
lactic acid bacteria (LAB) strains can activate the com-
mon mucosal immune system and, thus, influence sites
distant to the intestine, including the respiratory tract
[1,2]. Respiratory effects of probiotics in animal models
have included attenuating allergic airway responses and
protecting against respiratory pathogens [1,2]. Moreover,
several human trials have demonstrated that probiotics,
when taken prophylactically by healthy individuals in-
duce a beneficial effect on the severity and duration of
bacterial and viral respiratory infections reviewed in [3].
In this sense, our laboratory evaluated several Lactoba-
cillus strains isolated from goat’s milk according to their
capacity to modulate the mucosal immune system and
found that the oral administration of Lactobacillus rham-
nosus CRL1505 (Lr1505) was able to improve respiratory
immunity [4]. We observed that Lr1505 induced an in-
crease in the levels of interleukin (IL)-6, IL-4, IL-10 and
interferon (IFN)-γ in broncho-alveolar lavage fluid (BAL)
of treated mice. Moreover, Lr1505, administered by the
oral route at the proper dose, was able to increase Strepto-
coccus pneumoniae clearance rates in lung and blood,
improved survival of infected mice and reduced lung in-
juries [4,5]. We also conducted experiments aimed to
evaluate the effect of Lr1505 on the health of children
attending pre-school dining community centers. We
evaluate the impact of probiotic yogurt containing Lr1505
on mucosal immunity and we study the effect of this treat-
ment on gastrointestinal and respiratory infections, in
terms of number of episodes and severity [6,7]. Significant
differences were detected in the incidence of intestinal
and respiratory infections, especially those caused by
viruses, when the placebo and the probiotic treatments
were compared. These results indicate that Lr1505 can
improve resistance not only against bacterial respiratory
pathogens but to respiratory viruses as well [7].
Among respiratory viruses, influenza A virus and re-
spiratory syncytial virus (RSV) are the most important
cause of infant lower respiratory tract infection, causing
significant morbidity and mortality especially in develop-
ing countries [8,9]. Although genetically dissimilar, both
viruses generate double-stranded (ds) RNA replication
intermediates that act as toll-like receptor 3 (TLR3) and
retinoic acid-inducible gene I (RIG-I) ligands and contrib-
ute to immune system activation. Influenza A virus, a
single-stranded RNA virus has been shown to trigger type
I IFN through recognition by TLR3 and RIG-I in myeloid
dendritic cells (DCs), fibroblasts or alveolar epithelial cells
[10]. In addition, TLR3 expressed by respiratory epithelial
cells and DCs contributes at recognizing RSV during in-
fection by binding to viral RNA [11].Previous in vitro studies have shown that treatment of
murine or human primary respiratory epithelial cells or
cell lines with poly(I:C) induces secretion of multiple
chemokines, particularly monocyte chemotactic protein
(MIP)-1, RANTES and IL-8, together with increased ex-
pression of genes encoding TLRs, including TLR3 [12].
In vivo studies using mice have demonstrated that poly
(I:C) treatment results in TLR3- and CXCR2-dependent
neutrophilic pulmonary inflammation, interstitial edema,
bronchiolar epithelial hypertrophy, and altered lung
function [13,14]. These changes were accompanied by
elevated levels of pro-inflammatory cytokines and type I
interferons in BAL [13] and, increased airway epithelial
cell TLR3 protein expression [14]. These functional
changes are similar to those caused by RSV and there-
fore, nasal administration of the dsRNA analog poly(I:C)
has been used to mimic the pro-inflammatory and phy-
siopathological consecuences of RNA viral infections in
the lung.
As mentioned above, some studies have shown that
probiotics, including Lr1505, had the potential to benefi-
cially modulate the outcome of certain bacterial and
viral respiratory infections [3]. However, these studies
did not determine the mechanism(s) by which immuno-
biotics contribute to host defense against respiratory
viruses. An understanding of how the dialogue between
immunobiotics and the innate immune system is trans-
lated into beneficial/protective responses is required be-
fore we can achieve clinically effective bacteria-based
strategies that maintain and promote respiratory health.
In this sense, studying the effect of orally administered
probiotics on the immune response triggered by respira-
tory activation of TLR3/RIG-I would contribute to the
knowledge of the mechanism of probiotics’ protective ef-
fect against respiratory viral infections. Therefore, the
aim of the present study was to deepen the understand-
ing of the mechanisms of Lr1505 immunomodulatory
activity by evaluating: a) its effects on immune cell
populations in gut and lung; b) its ability to change the
cytokine profile in serum and the respiratory tract; c)
and its influence on the respiratory immune response
induced by intranasal challenge with the viral pathogen-
associated molecular pattern poly(I:C).
Methods
Microorganisms
Lactobacillus rhamnosus CRL1505 (Lr1505) and
CRL1506 (Lr1506) were obtained from the CERELA cul-
ture collection (Chacabuco 145, San Miguel de Tucu-
mán, Argentina). Both strains were isolated from goat
milk from northwestern Argentina and were selected be-
cause their immunomodulatory capacities [4]. The cul-
ture was kept freeze-dried and then rehydrated using the
following medium: peptone 15.0 g, tryptone 10.0 g, meat
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12 h at 37°C (final log phase) in Man-Rogosa-Sharpe
broth (MRS, Oxoid). The bacteria were harvested by
centrifugation at 3000 g for 10 min, washed three times
with sterile 0.01 mol/l phosphate buffer saline (PBS), pH
7.2, and resuspended in sterile 10% non-fat milk.
Animals and feeding procedures
Male 6-week-old BALB/c mice were obtained from the
closed colony kept at CERELA. They were housed in
plastic cages at room temperature. Mice were housed in-
dividually during the experiments and the assays for
each parameter studied were performed in 5–6 mice per
group for each time point. Lr1505 or Lr1506 was admi-
nistered to different groups of mice for 5 consecutive
days at a dose of 108 cells/mouse/day in the drinking
water [4,5]. The treated groups and the untreated con-
trol group were fed a conventional balanced diet ad libi-
tum. All experiments were carried out in compliance
with the Guide for Care and Use of Laboratory Animals
and approved by the Ethical Committee of Animal Care
at CERELA under the protocol BIOT-CRL/11.
Intransal administration of poly(I:C)
Mice were lightly anesthetized and 100 μl of PBS, con-
taining 250 μg poly(I:C) (equivalent to 10 mg/kg body
weight), was administered dropwise, via the nares. Con-
trol animals received 100 μl of PBS. Mice received three
doses of poly(I:C) or PBS with 24 hs rest period between
each administration.
Cytokine concentrations in serum, broncho-alveolar and
intestinal fluids
Blood samples were obtained through cardiac puncture
at the end of each treatment and collected in hepari-
nized tubes. BAL samples were obtained as described
previously [15]. Briefly, the trachea was exposed and
intubated with a catheter, and 2 sequential bronchoal-
veolar lavages were performed in each mouse by inject-
ing sterile PBS; the recovered fluid was centrifuged for
10 min at 900 x g; the pellet was used to make smears
that were stained for cell counts; and the fluid was fro-
zen at −70°C for subsequent antibody analyses. Intestinal
fluid samples were obtained as follows: the small intes-
tine was flushed with 5 ml of PBS and the fluid was cen-
trifuged (10,000 g, 4°C 10 min) to separate particulate
material. The supernatant was kept frozen until use.
Tumour necrosis factor (TNF)-α, IFN-α, IFN-β, IFN-γ,
IL-4, IL-6, IL-8, IL-10, IL-12 and MCP-1 concentrations
in serum, BAL and intestinal fluid, were measured with
commercially available enzyme-linked immunosorbent
assay (ELISA) technique kits following the manufac-
turer's recommendations (R&D Systems, MN, USA) [4].Leukocyte counts in the blood and BAL
Blood and BAL samples were obtained as described
above. The total number of leukocytes and differential
cell counts were performed as described previously [15].
Briefly, the total number of leukocytes was determined
with a hemocytometer. Differential cell counts were per-
formed by counting 200 cells in blood smears stained
with May Grunwald-Giemsa.
Biochemical assay of BAL fluid
Protein and albumin content, a measure to quantitate
increased permeability of the bronchoalveolar–capillarity
barrier, and lactate dehydrogenase (LDH) activity, an in-
dicator of general cytotoxicity, were determined in the
acellular BAL fluid [15]. Protein content was measured
by the bicinchoninic (BCA) protein assay (Pierce Bio-
technology Inc., Rockford, IL). Albumin content was
determined colorimetrically based on albumin binding
to bromcresol green using an albumin diagnostic kit
(Wiener Lab, Buenos Aires, Argentina). LDH activity,
expressed as units per liter of BAL fluid, was determined
by measuring the formation of the reduced form of nico-
tinamide adenine dinucleotide (NAD) using the Wiener
reagents and procedures (Wiener Lab).
Lung wet:dry weight ratio
Lung wet:dry weight ratio was measured as previously
described by Aeffner et al., [16]. Briefly, mice were
euthanized and exsanguinated, and their lungs removed,
weighed, and dried in an oven at 55°C for 7 days. After
drying, the lungs were weighed again. Wet:dry weight
ratio was then calculated as an index of intrapulmonary
fluid accumulation, without correction for blood
content.
Cell preparation
Single Peyer’s patches (PPs) and lung cells from mice
were prepared using the method described by Hori et al.
[17]. Mice were anaesthetized with diethyl ether and
killed the next day by exsanguination. Lungs were
removed, finely minced and incubated for 90 min with
300 U of collagenase (Yakult Honsha Co., Tokyo, Japan)
in 15 ml of RPMI 1640 medium (Sigma, Tokyo, Japan).
To dissociate the tissue into single cells, collagenase-
treated minced lungs were gently tapped into a plastic
dish. After removal of debris, erythrocytes were depleted
by hypotonic lysis. The cells were washed with RPMI
medium supplemented with 100 U/ml of penicillin and
100 mg/ml of streptomycin and then resuspended in a
medium supplemented with 10% heat-inactivated foetal
calf serum (FCS). Cells were counted using Trypan Blue
exclusion and then resuspended at an appropriate con-
centration of 5x106 cells/ml.
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Lung cell suspensions were pre-incubated with anti-
mouse CD32/CD16 monoclonal antibody (Fc block) for
15 min at 4°C. Cells were incubated in the antibody
mixes for 30 min at 4°C and washed with FACS buffer.
The following antibodies from BD PharMingen were
used: anti-mouse CD3-FITC, anti-mouse CD4-PE, anti-
mouse CD8-PE, anti-mouse IFN-γ-APC, anti-mouse
CD11b-FITC, anti-mouse CD11c-PE, anti-mouse IFN-γ-
PE, anti-mouse MHC-II-PE, anti-mouse IL-12-PE and
anti-mouse CD103-biotin. Following incubation with
biotinylated primary antibodies, the labeling was
revealed using streptavidin-PercP. In all cases, cells were
then acquired on a BD FACSCalibur™ flow cytometer
(BD Biosciences) and data were analyzed with FlowJo
software (TreeStar). The total number of cells in each
population was determined by multiplying the percen-
tages of subsets within a series of marker negative or
positive gates by the total cell number determined for
each tissue.
Statistical analysis
Experiments were performed in triplicate and results
were expressed as mean ± standard deviation (SD). After
verification of the normal distribution of data, 2-way
ANOVA was used. Tukey's test (for pairwise compari-
sons of the means) was used to test for differences be-
tween the groups. Differences were considered
significant at p < 0.05.
Results
L. rhamnosus CRL1505 and L. rhamnosus CRL1506
differentially modulate intestinal immunity
The immunomodulatory effects of Lr1505 and Lr1506
were determined in vivo using BALB/c mice. The ad-
ministration of both strains induced significant changes
in the profile of cytokines in the intestinal fluid. The
levels of IFN-α, IFN-β, IFN-γ and TNF-α were higher in
animals treated with Lr1505 or Lr1506 than in controls
(Figure 1A). Levels of TNF-α and type I interferons were
higher in Lr1506-treated mice than in the other experi-
mental groups, while Lr1505 strain was more effective
than Lr1506 for improving production of IFN-γ
(Figure 1A). On the other hand, only Lr1505 was able to
increase the levels of intestinal IL-6 (Figure 1A). When
studying the regulatory cytokines IL-10 and TGF-β we
observed that both strains were able to increase the
levels of IL-10 (Figure 1A), while lactobacilli treatments
did not modified the values of TGF-β (data not shown).
We also evaluated the changes induced by lactobacilli
in immune cell populations from PPs. Both Lr1505 and
Lr1506 increased the numbers of CD3+CD4+IFN-γ+ T
cells (Figure 1B). On the contrary, neither Lr1505 nor
Lr1506 induced changes in the number of CD3+CD8+IFN-γ+ T cells (Figure 1B). When we studied the effect
of lactobacilli on CD11chighCD11b+ dendritic cells (DCs)
from PPs, we observed no changes in the number of this
population (data not shown). However, both Lr1505 and
Lr1506 strains increased the expression of MHC-II and
CD80 and CD86 co-stimulatory molecules (Figure 2A).
We also observed increased levels of IFN-γ and IL-12 in
CD11chighCD11b+ DCs from Lr1505 treated mice, while
none of the strains modify the levels of IFN-β
(Figure 2B).
L. rhamnosus CRL1505 but not L. rhamnosus CRL1506
modulates respiratory immunity
We have previously shown that changes in the profile of
cytokines induced in intestine by LAB strains are
reflected in the blood [4]. Therefore, we also assessed
the levels of different cytokines in serum samples from
animals treated with Lr1505 or Lr1506 and controls. As
shown in Figure 3A, both strains increased the levels of
type I interferons, IFN-γ, IL-6 and IL-10 whereas no sig-
nificant differences were observed in the levels of IL-8
and MCP-1 (data not shown). Lr1506 administration
was more effective than Lr1505 to increase serum levels
of IFN-α and-β, whereas strain Lr1505 induced higher
levels of IFN-γ, IL-6 and IL-10 (Figure 3A). In addition,
only Lr1506 was able to increase serum TNF-α
(Figure 3A).
In order to evaluate the changes induced by LAB in
respiratory tract we determined the levels of different
cytokines in BAL (Figure 3B). Lr1506 treatment induced
no changes in any of the cytokines evaluated. On the
contrary, oral administration of Lr1505 induced
increases in levels of IL-6, IFN-γ and IL-10 in BAL
(Figure 3B). We also evaluated the changes induced by
both strains in lung immune cells using flow cytometry.
Orally administered Lr1505 was able to increase the
number of CD3+CD4+IFN-γ+ T cells in lungs while no
modifications were observed in the number of CD3
+CD8+IFN-γ+ T cells (Figure 4). Furthermore, Lr1506
was not able to induce changes in the number of lung T
cells. In lungs, two populations of DCs can be defined
using CD11c, CD11b, CD103 and MHC-II antibodies:
MHC-II+CD11c+CD11blowCD103+ and MHC-II+CD11c
+CD11bhighCD103- cells [17]. Therefore, we next aimed
to evaluate the effect of LAB on these populations of
DCs from lungs. Lactobacilli did not induce changes in
the number of lung CD11c+CD11blowCD103+ and
CD11c+CD11bhighCD103- DCs or modify the expression
of MHC-II in these DCs (data not shown).
Poly(I:C) induces pulmonary injuries and dysfunction that
are reduced by L. rhamnosus CRL1505 administration
Considering the ability of Lr1505 to stimulate respiratory
tract immunity and our previous studies in humans
Figure 1 Effect of lactobacilli on intestinal immunity. (A) Effect of Lactobacillus rhamnosus CRL1505 (Lr1505) or L. rhamnosus CRL1506 (Lr1506)
administration on the tumor necrosis factor (TNF)-α, interferon (IFN)-α, IFN-β, IFN-γ, interleukin (IL)-6, and IL-10 concentrations in intestinal fluid.
(B) Effect of Lr1505 or Lr1506 administration on CD3+CD8+IFN-γ+ and CD3+CD4+IFN-γ+ T cells from Peyer’s patches. The results represent data
from three independent experiments. Significant differences between lactobacilli-treated and control groups * (P< 0.05) or ** (P< 0.01).
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strain is able increase resistance to respiratory viral
infections in children [7], we next evaluated the effect of
Lr1505 on the immune response triggered by nasal ad-
ministration of the viral pathogen-associated molecular
pattern poly(I:C).
Previous studies from Aeffner et al., [16] demonstrated
that the nasal challenge of mice with poly(I:C) signifi-
cantly alters lungs function and induce lung injuries.
Our results are in line with that study since we observed
altered wet:dry weight ratio in poly(I:C)-challlenged mice
(Figure 5). Moreover, significantly increased levels of
protein and albumin concentrations as well as LDH ac-
tivity was found in BAL samples of challenged miceindicating that poly(I:C) produces an alteration of the
alveolar-capillary barrier and local cellular damage.
Lr1505 treatment decreased significantly the parameters
that we use to evaluate pulmonary damage, whereas
Lr1506-treated mice showed lung injuries similar to
those observed in the control group (Figure 5).
L. rhamnosus CRL1505 administration beneficially
modulates immune response triggered by nasal
administration of poly(I:C)
Lung tissue injuries induced by the nasal administration of
poly(I:C) has been associated to an exacerbated inflamma-
tory response [14,16]. Therefore, we next evaluated the pul-
monary immune response induced by the nasal challenge
Figure 2 Effect of lactobacilli on intestinal immunity. Effect of Lactobacillus rhamnosus CRL1505 (Lr1505) or L. rhamnosus CRL1506 (Lr1506)
administration on CD11chighCD11b+ dendritic cells from Peyer’s patches. Expression of MHC-II, CD80, CD86 (A) and IFN-γ, IL-12 and IFN-β (B) in
CD11chighCD11b+ cells. The results represent data from three independent experiments.
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First, we studied the levels of IFN-α, IFN-β, IFN-γ, IL-6, IL-
4, TNF-α, IL-1β, IL-8, MCP-1, IL-10 and TGF-β in BAL
and serum samples at different hours after poly(I:C) chal-
lenge (Figure 6). Nasal administration poly(I:C) significantly
increased respiratory levels of pro-inflammatory mediators
IL-6, TNF-α, IL-1β, IL-8 and MCP-1. No differences were
observed between the experimental groups when analyzing
IL-1β levels (data not shown). However, levels of IL-6,
TNF-α, IL-8 and MCP-1 were significantly higher in the
Lr1505 group when compared to controls (Figure 6A).
IFN-α, IFN-β and IFN-γ in BAL were also increased after
the challenge with poly(I:C) in all the experimental groups,
however, Lr1505 mice showed higher levels of BAL IFN-β
and IFN-γ than controls (Figure 6A). No changes were
observed in BAL IL-4 concentration during the studied
period (data not shown). Poly(I:C) challenge also induced
an increase in the respiratory levels of IL-10 and TGF-β in
all groups. Lr1505 treated mice presented levels of TGF-β
that were similar to those in controls (data not shown).
However, levels of IL-10 were significantly higher in Lr1505
treated mice (Figure 6A). Oral administration of Lr1506 did
not induce changes in the levels of respiratory cytokines
(Figure 6A).The nasal challenge with poly(I:C) also increased cyto-
kines levels in serum. Moreover, the effect of Lr1505
treatment on the production of these cytokines was
similar to that found in BAL (Figure 6B). Lr1505
induced increases in serum IFN-β, IFN-γ and IL-10,
while decreased production of TNF-α, IL-8 and MCP-1
when compared to controls (Figure 6B). In addition,
Lr1505 induced higher levels of serum IL-6 (Figure 6B).
We also evaluated the changes in lung immune cells
induced by nasally administered poly(I:C) (Figures 7, 8). The
numbers of total infiltrated cells, macrophages, neutrophils
and lymphocytes increased in a time-dependent manner in
all the experimental groups. The number of neutrophils in
Lr1505 treated mice present significant differences with re-
spect to the controls, showing higher values during the first
hours and then decreased numbers of cells by the end of the
studied period (Figure 7A). In addition, the number of BAL
lymphocytes was superior in Lr1505 treated mice when com-
pared to controls after hour 12 post-challenge (Figure 7A).
Poly(I:C) administration increased CD3+CD8+IFN-γ+ (data
not shown) and CD3+CD4+IFN-γ+ T cells (Figure 7B). How-
ever, Lr1505 treatment induced significantly higher levels
of lung CD3+CD4+IFN-γ+ T cells when compared to con-
trols (Figure 7B). Poly(I:C) challenge also increased the
Figure 3 Effect of lactobacilli on systemic and respiratory immunity. Effect of Lactobacillus rhamnosus CRL1505 (Lr1505) or L. rhamnosus
CRL1506 (Lr1506) administration on the tumor necrosis factor (TNF)-α, interferon (IFN)-α, IFN-β, IFN-γ, interleukin (IL)-6, and IL-10 concentrations in
serum (A) and broncho-alveolar lavages (B). The results represent data from three independent experiments. Significant differences between
lactobacilli-treated and control groups * (P< 0.05) or ** (P< 0.01).
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+CD11bhighCD103- DCs when compared to basal levels in all
the experimental groups (Figure 8A). Oral administration of
Lr1505 significantly increased the numbers of both popula-
tions of DCs cells in lungs when compared to controls
(Figure 8A). Moreover, this treatment improved expression
of MHC-II in both CD11c+CD11blowCD103+ and CD11c
+CD11bhighCD103- lung DCs. However, production of IL12
and IFN-γ was improved only in CD11c+CD11blowCD103+
cells (Figure 8B). On the contrary, no modifications in pul-
monary T cells and DCs were observed after oral treatment
with Lr1506 when compared to controls (Figures 7, 8).
Discussion
Several works have described different effects of probio-
tics on intestinal immune system from attenuating in-
flammatory responses to improving immunity [18-20].Previously, our laboratory evaluated the effect of the oral
administration of two Lactobacillus strains of the same
origin and with similar technological properties on the
production of IFN-γ, IL-4 and IL-10 in the intestine and
we demonstrated that Lr1505 and Lr1506 were able to
induce differential cytokine profiles in the gut [4]. The
first aim of our present research was to further evaluate
the changes induced by Lr1505 and Lr1506 in intestinal
immunity. In vivo experiments demonstrated that the
administration of lactobacilli strains significantly aug-
mented the expression of IFN-γ in PPs compared with
the control, confirming our previous results [4]. More-
over, Lr1505 was more efficient than Lr1506 for increas-
ing the levels of IFN-γ, IL-10 and IL-6 in the intestine. It
is well established that a high IL-12 production of DCs
by microbial stimuli gives rise to Th1 polarization and
thus a strong stimulation of the adaptive immune
Figure 4 Effect of lactobacilli on respiratory immunity. Effect of Lactobacillus rhamnosus CRL1505 (Lr1505) or L. rhamnosus CRL1506 (Lr1506)
administration on CD3+CD8+IFN-γ+ and CD3+CD4+IFN-γ+ T cells from lung. The results represent data from three independent experiments.
Significant differences between lactobacilli-treated and control groups * (P< 0.05).
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been reported to augment IL-12 and IFN-γ mRNA
expressions and CD4+ T cell-DCs interaction in PPs
[21]. Studies showed that probiotics are captured by
CD11c+ DCs in PPs and increase IL-12 production by
these antigen presenting cells. Subsequently, T cells re-
ceive the information from DCs, resulting in the im-
mune activation of CD4+ T and increased production of
IL-6 and IFN-γ [22]. Therefore, Lr1505 would be able toFigure 5 Effect of lactobacilli on lung injuries induced by the nasal ad
poly(I:C). Effect of Lactobacillus rhamnosus CRL1505 (Lr1505) or L. rhamnos
lactate dehydrogenase (LDH) activity and, albumin and protein concentrati
three independent experiments. Significant differences between lactobacillimprove intestinal Th1 immune response through this
mechanism and it would be more efficient than Lr1506.
On the contrary, Lr1506 showed a higher capacity to
improve levels of IFN-α, IFN-β and TNF-α in the gut
when compared with Lr1505. It was observed that cer-
tain lactobacilli trigger the expression of IFN-β in DCs
cells [23]. In our present analyses, we therefore expected
to find that Lr1506 was capable of increasing IFN-β
levels in DCs; however, we did not detected changes ofministration of the viral pathogen-associated molecular pattern
us CRL1506 (Lr1506) administration on lung wet:dry weight ratio,
ons in broncho-alveolar lavages (BAL). The results represent data from
i-treated and control groups * (P< 0.05).
Figure 6 Effect of lactobacilli on the production of cytokines induced by the nasal administration of the viral pathogen-associated
molecular pattern poly(I:C). Effect of Lactobacillus rhamnosus CRL1505 (Lr1505) or L. rhamnosus CRL1506 (Lr1506) administration on the tumor
necrosis factor (TNF)-α, interferon (IFN)-β, IFN-γ, interleukin (IL)-6, IL-8, IL-10 and monocyte chemotactic protein (MCP)-1 concentrations in serum
(A) and broncho-alveolar lavages (B). The results represent data from three independent experiments.
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mice. Therefore, the increased levels of intestinal IFN-β
observed in our in vivo experiments could indicate that
the production of this cytokine is in charge of intestinal
epithelial cells (IEC). In this sense, we have evaluated the
effect of different LAB strains on bovine and porcine
IEC and we found that different LAB strains had distinct
effects on cytokine production by these cells. Notably,
some strains such as L. casei MEP221106 and L. rham-
nosus LA-2 were able to increase IFN-β production in
IEC [20,24]. Moreover, we also evaluated the response of
IEC to poly(I:C) challenge and found that L. casei
MEP221106 and L. rhamnosus LA-2 improved the levels
of IFN-α, IFN-β and TNF-α in porcine and bovine IEC
respectively [20,24]. Considering that IFN-β gives rise to
the up-regulation of a vast number of genes involved in
viral defense but also genes of major importance for the
development of a strong cellular (Th1) response,including the expression of IL-12 and CXCL10, we can
speculate that Lr1506 may play an important role in the
improvement of innate and specific immune responses
against intestinal virus. In addition, our results demon-
strated that Lr1505 and Lr1506 have the ability to im-
prove intestinal antiviral immunity by using different
mechanisms (Figure 9).
When we evaluated the levels of serum cytokines we
found that Lr1506 was more efficient than Lr1505 to in-
crease IFN-α, IFN-β and TNF-α, while serum IFN-γ, IL-
10 and IL-6 levels were more efficiently improved by
Lr1505. These changes in the profile of serum cytokines
was similar to those found in the intestinal fluid, indicat-
ing that levels of serum cytokines are a reflection of in-
testinal changes and confirming our previous findings in
this regard (4). On the contrary, the analysis of respira-
tory cytokines showed that only Lr1505 was able to in-
crease the levels of IFN-γ, IL-10 and IL-6. While these
Figure 7 Effect of lactobacilli on lung immune cells recruitment induced by the nasal administration of the viral pathogen-associated
molecular pattern poly(I:C). Effect of Lactobacillus rhamnosus CRL1505 (Lr1505) or L. rhamnosus CRL1506 (Lr1506) administration on the number
of leukocytes, lymphocytes, neutrophils and macrophages after the challenge with poly(I:C) (A). Effect of Lr1505 or Lr1506 administration on CD3
+CD4+IFN-γ+ T cells from lung after the challenge with poly(I:C) (B). The results represent data from three independent experiments. Significant
differences between lactobacilli-treated and control groups * (P< 0.05).
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in serum, we can not attribute a direct correlation be-
tween the two increases, as we did not found increased
levels of IFN-α, IFN-β or TNF-α in the respiratory tract
of Lr1506 treated mice. Therefore, and taking into ac-
count the capacity of Lr1505 of increasing the number
of CD3+CD4+IFN-γ+ T cells in PPs, we hypothesized
that Lr1505 would be able to induce a mobilization of
these cells into the respiratory mucosa. We demon-
strated that this hypothesis was true since increased
numbers of CD3+CD4+IFN-γ+ T were found in lungs of
Lr1505 treated mice. Considering that several studies
reported that oral administration of probiotic strains
increased protection against influenza virus infection in
mice by increasing NK cell activity and IFN-γ produc-
tion in lung [17,21,25], we can speculate that the
mobilization of CD3+CD4+IFN-γ+ T cells from the intes-
tine to the airways and the improved production of IFN-
γ could be involved in the protective effect against viral
infections induced by Lr1505 that was observed in clin-
ical studies [7]. Moreover, the increased levels of serumIFN-β induced by this strain could also involved in its
protective effect since it was demonstrated that the oral
administration of L. plantarum L-137 enhanced protec-
tion against influenza virus infection in correlation with
an increase in IFN-β production in the serum of infected
mice at an early stage after infection [26].
To mimic the pro-inflammatory and physiopathologi-
cal consecuences of RNA viral infections in the lung, we
used an experimental model of lung inflammation based
on the administration of the artificial TLR3/RIG-I ligand
and dsRNA analog poly(I:C). In our experiments, admin-
istration of poly(I:C) to the lungs of mice induced a
marked impairment of lung function that was accom-
panied by the production of pro-inflammatory mediators
and inflammatory cell recruitment into the airways in
accordance with results published by Stowell et al. [14].
Exposure to poly(I:C) induced respiratory epithelial cell
death and impaired epithelial barrier function as demon-
strated by the increased levels LDH activity and albumin
concentration in BAL. Moreover, intranasal administra-
tion of three once-daily doses of poly(I:C) resulted in an
Figure 8 Effect of lactobacilli on lung dendritic cells activation induced by the nasal administration of the viral pathogen-associated
molecular pattern poly(I:C). Effect of Lactobacillus rhamnosus CRL1505 (Lr1505) or L. rhamnosus CRL1506 (Lr1506) administration on the number
of pulmonary CD11c+CD11blowCD103+ and CD11c+CD11bhighCD103- dendritic cells after the challenge with poly(I:C) (A). Effect of Lr1505 or
Lr1506 administration on the expression of MHC-II, IFN-γ and IL-12 in pulmonary CD11c+CD11blowCD103+ and CD11c+CD11bhighCD103- dendritic
cells after the challenge with poly(I:C) (B). The results represent data from three independent experiments. Significant differences between
lactobacilli-treated and control groups * (P< 0.05).
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Figure 9 Proposed mechanism for the improvement of antiviral immunity by orally administered lactobacilli. Enhancement of intestinal
antiviral immunity by Lactobacillus rhamnosus CRL1506 (A). Enhancement of intestinal and respiratory antiviral immunity by Lactobacillus
rhamnosus CRL1505 (B). Orally administered L. rhamnosus CRL1505 stimulates the Th1 response in the gut and to induce mobilization of Th1 cells
from inductive sites in the gut to effector sites in the respiratory tract. These activated Th1 cells would produce cytokines (IFN-γ) able to stimulate
the activity of local respiratory immune cells such as alveolar macrophages, NK cells and CD11c+CD11blowCD103+ dendritic cells. These previously
activated immune cells would be able to efficiently phagocyte pathogens that reach the alveolar space, induce specific immune responses and
increase the resistance to bacterial and viral respiratory infections.
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total cellularity in the BAL samples was due to a signifi-
cant influx of neutrophils and mononuclear cells.
In vitro studies have demonstrated that stimulation of
lung epithelial cells with poly(I:C) elicited the secretion
of multiple cytokines, chemokines, the induction of tran-
scription factors and increased expression of TLRs [12].
In our in vivo model increased levels of TNF-α, IL-6, IL-
8 and MCP-1 were observed in the respiratory tract,
therefore a likely source of cytokines following poly(I:C)
administration may be the airway epithelium. In
addition, the experimental model used in this work
resembles RSV infection since this respiratory virus is
able to induce a profile of pro-inflammatory cytokines
similar to that observed following in vivo poly(I:C) chal-
lenge in mice [14,16]. In fact, natural human RSV infec-
tion in children and experimental RSV inoculation in
mice result in prominent local secretion of pro-
inflammatory cytokines, such as TNF-α, IL-6, and CXC/
CC chemokines, including IL-8, MIP-1, RANTES, and
MCP-1. The coordinated actions of several of these
cytokines strongly promote the recruitment and activa-
tion of neutrophils and monocytes/macrophages [27],
also observed in our experimental model.
During acute viral lung infection, it is imperative that the
host’s inflammatory response is tightly regulated, enabling
pathogen elimination but limiting the detrimental effects of
inflammation on the gas exchange. An appropriate balance
of anti-inflammatory and pro-inflammatory mediators is es-
sential for a safe and effective antiviral immune response.
Thus, an excessive TNF-α/IL-8/MCP-1 response can leadto increased immunopathology, while exuberant IL-10 pro-
duction can result in delayed pathogen clearance [28]. In
this sense, it has been shown that TNF-α contributes to
clearance of the virus during the early stages of RSV infec-
tion, which is most likely a result of the NK cell response.
But continued production of TNF-α exacerbates illness and
tissue injuries during the late stages of RSV infection [29].
Interestingly, recent studies demonstrate a role for IL-10
in controlling immunopathology during respiratory viral
infections. Sun et al. [30] showed that IL-10 prevents
immunopathology and lethal disease during acute influ-
enza virus infection. On the other hand, IL-10 also seems
to play a crucial role in controlling disease severity in
RSV infection [31,32]. It was found that IL-10 deficiency
during RSV challenge did not affect viral load, but led to
markedly increased disease severity with enhanced weight
loss, delayed recovery and a greater influx of inflammatory
cells into the lung and airways and enhanced release of
inflammatory mediators [33].
The preventive administration of Lr1505 reduced the
production of TNF-α, IL-6, IL-8 and MCP-1 in the re-
spiratory tract after the challenge with poly(I:C). There-
fore, the reduction of these pro-inflammatory mediators
could explain at least partially the reduced lung injuries in
the Lr1505 treated group. Moreover, Lr1505 treatment
prior to poly(I:C) challenge induced a significant increase
in IL-10 in lung and serum. Consequently, IL-10 would be
valuable for attenuating inflammatory damage and patho-
physiological alterations in lungs challenged with the viral
pathogen-associated molecular pattern poly(:IC). Accord-
ing to these results, Lr1505 treatment would beneficially
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and IL-10, allowing an effective inflammatory response
against infection and avoiding tissue damage.
We also observed that the oral treatment with Lr1505
increased levels of IFN-γ in BAL after poly(I:C) challenge.
This is in line with reports that showed improved produc-
tion of IFN-γ after respiratory viral challenge in probiotic
treated mice [17,21,25]. The higher levels of respiratory
IFN-γ after poly(I:C) challenge in Lr1505 treated mice
could be explained by the higher number of CD3+CD4
+IFN-γ+ T cells and by an improved activation of these
cells by lung DCs. In the lung, DCs are the most potent
antigen presenting cells playing a central role in initiating
the primary immune response. In the mouse lung, several
recent studies have demonstrated the existence of two
major DCs subsets identified as MHC-II+CD11c+
CD11blowCD103+ (CD103+ DCs) and MHC-II+CD11c+
CD11bhighCD103- (CD11bhigh DCs) cells [34]. Moreover,
recent studies by Furuhashi et al. [35] suggested that lung
CD103+ DCs are more potent at eliciting Th1 and Th17
responses than CD11bhigh DCs, whereas CD11bhigh DCs
are more efficient at evoking a Th2 response under steady
state. When we analyzed lung DCs in Lr1505 treated mice
after the nasal challenge with poly(I:C) we found increased
levels of both CD103+ and CD11bhigh DCs. Moreover, both
DCs populations showed higher expression of MHC-II
when compared with controls. However, IL-12 and IFN-γ
were increased only in CD103+ DCs. Consistent our
results it has been demonstrated that CD4
+CD62LhighDO11.10 T cells that have been primed with
lung CD103+ DCs induced higher frequencies of CD4+ T
cells producing IFN-γ than IL-4 [35].
An other possible source of IFN-γ in poly(I:C) chal-
lenged mice are NK cells. Similar to our work, Takeda
et al., [36] showed that the oral administration of L.
plantarum 06CC2 is able to increase IFN-γ expression
in PPs and lungs. Improved respiratory IFN-γ induced
by 06CC2 strain was associated with augmentation of
NK cell activity and correlated with the alleviation of in-
fluenza infection in mice [36]. In addition, it was
demonstrated that feeding mice with L. pentosus signifi-
cantly enhances NK activity and that the increase in
IFN-γ production by these cells did not occur through
direct action of L. pentosus on NK cells but was
dependent on IL-12 produced by intestinal CD11c+ DCs
following the interaction between the DC and LAB [37].
Further detailed studies are required to clarify whether
Lr1505 is able to increase NK cell activities and protect
mice against respiratory viruses challenges.
Conclusions
Recent evidence showed that pattern recognition
receptors-mediated sensing of resident commensal
microbiota in the steady state regulates the developmentand function of innate and adaptive immune systems in
extra-intestinal sites, and prepares the host to defend
against intrusion by pathogenic microorganisms [2,38].
In mice, depletion of gut microbiota by antibiotics can
result in reduced surface expressions of TLR2 and TLR4
in peritoneal macrophages, and less inflammation fol-
lowing intraperitoneal LPS injection in vivo [39], indicat-
ing that intestinal microbiota can constitutively prime
peritoneal macrophages in preparation for pathogen in-
vasion. In addition, recognition of peptidoglycan from
the microbiota by Nod-1 primes systemic innate im-
munity by enhancing the cytotoxicity of bone marrow-
derived neutrophils in response to systemic infection
with the bacterial pathogens, Streptococcus pneumoniae
and Staphylococcus aureus [40]. Moreover, recent studies
characterized the cellular and molecular mechanism by
which the gut microbiota regulate respiratory tract im-
mune defense against influenza virus infections and
found that hat neomycin-sensitive bacteria in the gastro-
intestinal tract are required for supporting immune
responses to respiratory influenza infection [41]. Collect-
ively, these studies indicate that the gut microbiota sup-
port systemic and respiratory immunity by releasing low
levels of PRR ligands in circulation.
Although our studies do not allow us to discard this
mechanism for Lr1505, in the present work we propose
a different mechanism influencing antiviral immune re-
sponse in the respiratory tract. Our results showed that
there would be a mobilization of cells from intestine and
changes in cytokine profile that would be able to bene-
ficially modulate the respiratory mucosal immunity
(Figure 9). Activation of respiratory immunity by orally
administered probiotics would have a complex mech-
anism, probably related to specific strains. Although
deeper studies are needed using challenges with re-
spiratory viruses, the results in this study suggest that
Lr1505, a potent inducer of antiviral cytokines, may be
useful as a therapeutic or prophylactic agent to control
respiratory virus infection.
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